Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis

Archives of Neurology
D J LangeS H Appel

Abstract

The cause of amyotrophic lateral sclerosis (ALS) is not known, and there is no effective treatment. Cell death may be caused by oxidative damage. Selegiline hydrochloride (Eldepryl) is a monoamine oxidase-B inhibitor with antioxidant properties. To determine if selegiline affects the clinical course of patients with ALS. Six-month, double-blind, placebo-controlled study of 133 patients with classical ALS and symptoms for less than 3 years. The primary end point to indicate effectiveness was the rate of change of the Appel ALS total score, an index of disease severity that incorporates strength and function in limbs, respiratory function, and bulbar function. Of the 133 patients, 67 were randomized to receive selegiline and 66 to receive placebo. One hundred four patients (53 in the selegiline group and 51 in the placebo group) completed the 6-month trial. Both groups were comparable for baseline characteristics and mean Appel ALS total score (70.5 points for the selegiline group and 70.6 for the placebo group). There was no difference in the rate of progression as measured by the Appel ALS total score, showing an average increase of 22 points in 6 months. The monthly rate of change was 3.4 for the selegiline group and 3.5 for t...Continue Reading

Citations

Jan 5, 2002·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·M J Strong
Feb 18, 2006·Journal of Neurology, Neurosurgery, and Psychiatry·A CzaplinskiS H Appel
Nov 21, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Swati Aggarwal, Merit Cudkowicz
Jun 15, 2006·Journal of Neurology·Adam CzaplinskiStanley H Appel
Nov 30, 2000·Current Treatment Options in Neurology·B M Demaerschalk, M J Strong
Jul 5, 2005·Expert Opinion on Investigational Drugs·E C Lai
Nov 30, 2004·Expert Opinion on Investigational Drugs·Michael J Strong
Jul 5, 2005·Expert Opinion on Investigational Drugs·M B Bromberg
Aug 3, 2011·Expert Opinion on Emerging Drugs·Ali Aamer Habib, Hiroshi Mitsumoto
Oct 22, 2002·Expert Opinion on Investigational Drugs·Mandy JacksonJeffrey D Rothstein
Oct 22, 2002·Expert Opinion on Investigational Drugs·Bernd Moosmann, Christian Behl
Jul 9, 2008·Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·Richard W OrrellMark Ross
Jun 25, 2008·Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·Veena Lanka, Merit Cudkowicz
Dec 9, 2009·Free Radical Biology & Medicine·Siân C Barber, Pamela J Shaw
Feb 26, 2013·Journal of Internal Medicine·M Lagouge, N-G Larsson
Apr 23, 2004·Expert Opinion on Pharmacotherapy·Michael D WeissGregory T Carter
Nov 22, 2007·Expert Opinion on Therapeutic Targets·Juan C CoronaRicardo Tapia
Jul 23, 2015·Molecular Neurobiology·Ewa NiedzielskaMałgorzata Filip
Jun 26, 2013·Free Radical Biology & Medicine·Emanuele D'AmicoHiroshi Mitsumoto
May 23, 2006·Biochimica Et Biophysica Acta·Siân C BarberPamela J Shaw
Jun 9, 2017·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Faiza ShafiqPanagiotis Zis
Sep 1, 2017·Muscle & Nerve·Sabrina PaganoniUNKNOWN Pooled Resource Open-Access ALS Clinical Trials Consortium
Sep 13, 2006·Muscle & Nerve·Adam CzaplinskiStanley H Appel
Feb 22, 2008·Muscle & Nerve·Andrei VoustianioukDale J Lange
Mar 23, 2006·Nature Reviews. Neuroscience·Moussa B H YoudimKeith F Tipton
Dec 2, 2005·Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases·Mamede de CarvalhoMichael Swash
Feb 19, 2014·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·John Turnbull
Jan 27, 2007·The Cochrane Database of Systematic Reviews·R W OrrellM Ross
Apr 20, 2012·The Cochrane Database of Systematic Reviews·Reto BaldingerMarkus Weber
Feb 12, 2020·Medicinal Research Reviews·Heike J WobstJames Shorter
Oct 22, 2003·Current Opinion in Rheumatology·Ericka P SimpsonStanley H Appel
Jul 27, 2001·Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases·E P Pioro
Jan 23, 2009·The Cochrane Database of Systematic Reviews·Michael BenatarDan H Moore
Jun 5, 2003·Pharmacology & Therapeutics·Michael J Strong
Jul 3, 2021·International Journal of Molecular Sciences·Christine Péladeau, Jagdeep K Sandhu
May 30, 2021·The Journal of Pharmacy and Pharmacology·Sudhanshu SharmaPravir Kumar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.